Mankind Pharma has received approval from the Competition Commission of India (CCI) to acquire Bharat Serums and Vaccines for Rs 13,630 crore. Mankind Pharma, a listed company, focuses on developing, manufacturing, and marketing a wide array of pharmaceutical products. The CCI confirmed this acquisition in a post on X.

Bharat Serums and Vaccines Ltd (BSV) is involved in research, development, licensing, manufacturing, importing, exporting, marketing, and distribution of pharmaceutical formulations. BSV is a leader in biopharmaceuticals, particularly in women’s healthcare, assisted reproductive treatment, critical care, and emergency medicine. This acquisition will enhance Mankind Pharma’s position in these sectors.

Strategic Acquisition for Mankind Pharma

In July, Mankind Pharma announced its plan to fully acquire Bharat Serums and Vaccines from Advent International. The deal is valued at approximately Rs 13,630 crore. This acquisition will provide Mankind Pharma with access to high-entry barrier products in critical care and established complex R&D technology platforms.

Mankind Pharma’s subsidiaries are also involved in producing active pharmaceutical ingredients (APIs), pharmaceutical intermediaries, and packaging products. The acquisition aligns with Mankind’s strategy to strengthen its presence in the Indian women’s health and fertility drug market.

Regulatory Approval Process

Acquisitions exceeding certain thresholds require CCI approval to ensure fair competition and prevent unfair business practices. The CCI monitors such deals to maintain a competitive marketplace. This acquisition marks a significant step for Mankind Pharma in expanding its product offerings and market reach.

The definitive agreement between Mankind Pharma and Bharat Serums and Vaccines involves acquiring a 100% stake for an enterprise value of around Rs 13,630 crore. This strategic move positions Mankind as a leader in the Indian pharmaceutical industry.

This acquisition is expected to enhance Mankind Pharma’s capabilities in women’s healthcare and critical care sectors. It will also provide opportunities for growth in other high-demand areas within the pharmaceutical industry.